Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA 24: Nexiguran Ziclumeran for ATTR-CM
Author(s): Marianna Fontana Added: 5 months ago
AHA Conference 2024 - Safety and efficacy outcomes of nexiguran ziclumeran (NTLA-2001) in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).Dr Marianna Fontana (University College London, London, UK) joins us onsite at AHA Conference to discuss the findings from the nexiguran ziclumeran for ATTR-CM trial (NCT04601051).Dr Fontana discusses a phase 1, ongoing, open-label, single… View more

Heart Failure
Potential Reversibility of ATTR-CM through Anti-ATTR Amyloid Antibodies
Author(s): Marianna Fontana Added: 1 year ago
Prof Marianna Fontana (University College London, UK) joined us to discuss the discovery and impact of antibody-associated reversal of ATTR amyloidosis–related cardiomyopathy in three patients. Prof Fontana and her team, in a correspondence published in The New England Journal of Medicine, revealed the identification of an antibody linked to the spontaneous reversal of cardiac transthyretin… View more

Heart Failure
ESC 23: ATTRibute-CM Trial
Author(s): Julian Gillmore Added: 1 year ago
ESC 2023 — Prof Julian Gillmore (University College London, UK) joins us onsite to discuss the findings of the ATTRibute-CM Study (NCT03860935). ATTRibute-CM was a randomised double-blind trial which aimed to evaluate the safety and efficacy of acoramidis in a cohort of patients diagnosed with transtherytin amyloid cardiomyopathy (ATTR-CM). 632 patients were enrolled in the trial, and were… View more

Heart Failure
AHA 23: Screening for Peripartum Cardiomyopathies Using an AI Enanced Digital Stethoscope
Author(s): Demilade Adedinsewo Added: 1 year ago
AHA 23 - We are joined by Dr Demilade Adedinsewo (Mayo Clinic, US) to discuss the findings from a study investigating the effectiveness of an artificial intelligence-enabled ECG (AI-ECG) for cardiomyopathy detection in an obstetric population.In the intervention arm, the digital stethoscope correctly identified 92% of those with ejection fraction <50% and 100% of those with ejection fraction … View more

Demographic

Heart Failure
Updates in HCM Management
Author(s): Elena Arbelo , Juan-Pablo Kaski Start date: Aug 27, 2023
Live from ESC 2023 in Amsterdam, this broadcast will bring together the chairpersons of the latest ESC Guidelines on Cardiomyopathy, released on Sunday 27 August 2023. Prof Elena Arbelo (Hospital Clinic, Barcelona, ES) andProf Juan Pablo Kaski (University College London, UK) will provide definitive commentary on the guideline updates – including what's new in hypertrophic cardiomyopathy (HCM),… View more

Guidelines & Statements

Heart Failure
ACC 25: The MyPEAK-1 Study
Author(s): Milind Y Desai Added: 1 month ago
ACC 2025 - First-in-human results from MyPEAK-1 show Tn-201 treatment in adults with Mybpc3-associated hypertropic cardiomyopathy was feasible and safe.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at ACC 2025 to discuss phase Ib/2a results from the first-in-human, non-randomized study investigating the safety and early efficacy of Tn-201, an adeno-associated virus serotype 9 gene… View more

Heart Failure
HFA 23: REDWOOD-HCM-Cohort 4: Aficamten in symptomatic nHCM
Author(s): Ahmad Masri Added: 1 year ago
ESC-HFA 23 — We are joined by Dr Ahmad Masri (Oregon Health & Science University Medical Group, US) to discuss the findings from REDWOOD-HCM cohort 4 (NCT04219826). This study assessed the safety and tolerability of the selective inhibitor of cardiac myosin, aficamten (Cytokinetics) in patients with symptomatic nHCM. Cohort 4 included 41 patients. The data presented at HFA 23 shows that… View more

Heart Failure
Dr Phillip Cuculich
Dr Phillip Cuculich graduated from Vanderbilt University School of Medicine, Nashville, USA in 2001 and has since trained at Northwestern University, Chicago and the Barnes-Jewish Hospital, Washington University, St Louis, USA where he is currently an Associate Professor of Medicine in the Cardiovascular Division. His clinical interests include arrhythmias, sudden cardiac death, atrial… View more
Alcohol and Heart Failure
Author(s): Debar Rasoul , Ashwin Ajay , Alend Abdullah , et al Added: 1 year ago

Heart Failure
Sanjay Prasad
Job title: Consultant in cardiology and cardiovascular magnetic resonance Professor of cardiomyopathy
Dr. Sanjay Prasad ran the Virgin London Marathon in 2016 to raise money for the Alexander Jansons Foundation, an organisation which was set up to fund research conducted by the Royal Brompton Hospital into causes, prevention and cures for Myocarditis.¹ He is also a musician and used to play in a jazz band. Academic History Dr. Prasad studied for his medical degree at the University of Wales in… View more